KR950032176A - 3-인돌릴피페리딘 - Google Patents

3-인돌릴피페리딘 Download PDF

Info

Publication number
KR950032176A
KR950032176A KR1019950009554A KR19950009554A KR950032176A KR 950032176 A KR950032176 A KR 950032176A KR 1019950009554 A KR1019950009554 A KR 1019950009554A KR 19950009554 A KR19950009554 A KR 19950009554A KR 950032176 A KR950032176 A KR 950032176A
Authority
KR
South Korea
Prior art keywords
formula
compound
indolyl
physiologically acceptable
general formula
Prior art date
Application number
KR1019950009554A
Other languages
English (en)
Other versions
KR100361950B1 (ko
Inventor
뵈트허 헨닝
매르즈 요아힘
제이프리트 크리스토프
그라이너 하르트무트
바르토스지크 게르트
Original Assignee
위르겐 호이만, 라인하르트 쉬틀러
메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프퉁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 위르겐 호이만, 라인하르트 쉬틀러, 메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프퉁 filed Critical 위르겐 호이만, 라인하르트 쉬틀러
Publication of KR950032176A publication Critical patent/KR950032176A/ko
Application granted granted Critical
Publication of KR100361950B1 publication Critical patent/KR100361950B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

일반식(I)의 3-인돌릴피페리딘:
(상기 식에서, R1, R2, R3그리고 R4는 각각 상호 독립적으로 H, A, OH, OA, F, Cl, Br, I, CN, CF3, COOH, CONH2, CONHA, CONA2또는 COOA, 또는 R1그리고 R2또한 R3그리고 R4는 각 경우 함께 또는 메틸렌디옥시이고, R5는 H 또는 OH이고, R6는 H 또는 R5그리고 R6함께는 또한 결합이고, A는 탄소수 1 내지 6을 가지는 알킬기이고, 그리고 n은 2,3,4,5또는 6이다) 및 이들 생리학적으로 허용되는 염은 중추신경계, 특히 도파민 효능 또는 도파민-길항작용을 나타낸다.

Description

3-인돌릴피페리딘
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 일반식(I)의 3-인돌릴피페리딘 및 이들의 생리학적으로 허용되는 염:
    (상기 식에서, R1, R2, R3및 R4는 각각 상호 독립적으로 H, A, OH, OA, F, Cl, Br, I, CN, CF3, COOH, CONH2, CONHA, CONA2또는 COOA, 또는 R1및 R2또한 R3및 R4는 각 경우 함께 또는 메틸렌디옥시이고, R5는 H 또는 OH이고, R6는 H 또는 R5및 R6는 함께 또한 결합이고, A는 탄소수 1 내지 6인 알킬기이고, 그리고 n은 2,3,4,5 또는 6이다)
  2. 제1항에 있어서, 상기한 3-인돌릴피페리딘이 (a)3-(1-(3-(5-카르바모일-3-인돌릴)프로필)-피페리드-4-일)인돌-5-카르복스아미드; (b)3-(1-(3-(5-카르바모일-3-인돌릴)프로필)-피페리드-4-일)인돌-5-카르보니트릴; (c)3-(1-(4-(5-메톡시카르보닐-3-인돌릴)부틸)-피페리드-4-일)인돌-5-메톡시인돌; (d)3-(1-(3-(5-에톡시카르보닐-3-인돌릴)프로필)-피페리드-4-일)인돌-5-카르복스아미드; (e)3-(1-(4-(5-시아노-3-인돌릴)부틸피페리드-4-일)인돌-5-카르보니트릴 중의 어느 하나 또는 이들의 생리학적으로 허용되는 염들인 것을 특징으로 하는 3-인돌릴피페리딘.
  3. 제1항에 따른 일반식(I)의 3-인돌릴피페리딘 유도체 및 이들 염의 제조방법에 있어서, 다음 일반식(Ⅱ)의 화합물:
    (상기 식에서, X1은 X 또는 NH2이고, X는 Cl, Br, I, OH 또는 반응기를 형성하기 위해 기능적으로 변형된 OH기이고, R1, R2및 n은 상기한 바와 같다)을 다음 일반식(Ⅲ)의 화합물과 반응시키거나,
    (상기 식에서, X2및 X3는 같거나 또는 상이할 수 있으며, 그리고 X1=NH2인 경우 각각 X이거나 또는 다른 경우에는 함께 NH이고, R3및 R4는 상기한 바와 같다), 또는 다음 일반식(Ⅳ)의 화합물:
    (상기 식에서, R1, R2그리고 n은 상기한 바와 같다)을 다음 일반식(Ⅴ)의 인돌과 반응시키거나,
    (상기 식에서, R3및 R4는 상기한 바와 같다) 또는 R5가 OH이고, R6가 수소인 일반식(I)의 화합물을 탈수에 의해 일반식(I)의 다른 화합물로 전화시키거나, 또는 하나 이상의 수소원자가 하나 이상의 환원성기 및/또는 하나 이상의 부가적 C-C 및/또는 C-N결합으로 치환된 것 이외의 일반식(I)을 가지는 화합물을 환원제로 처리하거나, 또는 하나 이상의 수소원자가 하나 이상의 가용매분해성기로 치환된 것 이외의 일반식(I)을 가지는 화합물을 가용매분해제로 처리하거나, 및/또는 R1, R2, R3및/또는 R4가 에스테르화, 가수분해, 에테르화, 에테르 절단, 완전 또는 부분가수분해 또는 알킬화에 의해 다른 라디칼(들) R1, R2, R3및/또는 R4로 전환시키거나, 및/또는 생성된 일반식(I)의 염기 또는 산을 산 또는 염기로 처리하여 이들 염증의 하나로 전환시키는 것을 특징으로 하는 일반식(I)의 3-인돌릴피페리딘 유도체 및 이들 염의 제조방법.
  4. 제1항에 의한 일반식(I)의 화합물 및/또는 이들의 생리학적으로 허용되는 염을 하나 이상의 고체, 액체 또는 반액체 부형제 또는 보조제와 함께 적합한 투여형태로 전환하는 것을 특징으로 하는 약학적 제형의 제조방법.
  5. 제1항에 따른 일반식(I)의 화합물 1종 이상 및/또는 이들의 생리학적으로 허용되는 염증 하나를 함유하는 것을 특징으로 하는 약학적제형.
  6. 제1항에 따른 일반식(I)의 화합물 또는 이들의 생리학적으로 허용되는 들을 약물의 제조에 사용하는 용도.
  7. 제1항에 따른 일반식(I)의 화합물 또는 이들의 생리학적으로 허용되는 염들을 질병의 치료에 사용하는 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950009554A 1994-04-22 1995-04-22 3-인돌릴피페리딘 KR100361950B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4414113A DE4414113A1 (de) 1994-04-22 1994-04-22 3-Indolylpiperidine
DEP4414113.0 1994-04-22

Publications (2)

Publication Number Publication Date
KR950032176A true KR950032176A (ko) 1995-12-20
KR100361950B1 KR100361950B1 (ko) 2003-02-05

Family

ID=6516183

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950009554A KR100361950B1 (ko) 1994-04-22 1995-04-22 3-인돌릴피페리딘

Country Status (20)

Country Link
US (1) US5693655A (ko)
EP (1) EP0683166B1 (ko)
JP (1) JPH07291969A (ko)
KR (1) KR100361950B1 (ko)
CN (1) CN1047385C (ko)
AT (1) ATE172730T1 (ko)
AU (1) AU697749B2 (ko)
CA (1) CA2147451C (ko)
CZ (1) CZ285369B6 (ko)
DE (2) DE4414113A1 (ko)
DK (1) DK0683166T3 (ko)
ES (1) ES2125508T3 (ko)
HU (1) HUT74096A (ko)
NO (1) NO307831B1 (ko)
PL (1) PL180781B1 (ko)
RU (1) RU2151148C1 (ko)
SK (1) SK280881B6 (ko)
TW (1) TW401416B (ko)
UA (1) UA41333C2 (ko)
ZA (1) ZA953260B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4414113A1 (de) * 1994-04-22 1995-10-26 Merck Patent Gmbh 3-Indolylpiperidine
GB9523462D0 (en) * 1995-11-16 1996-01-17 Merck Sharp & Dohme Therapeutic agents
ZA9711376B (en) 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives
DE19707628A1 (de) * 1997-02-26 1998-08-27 Merck Patent Gmbh Oxazolidinone
AU736596B2 (en) * 1997-07-25 2001-08-02 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
BR9811557A (pt) * 1997-08-15 2000-08-22 Pfizer Prod Inc Derivados do 2-)4-aril ou heteroaril-piperazin-1-ilmetil)-1h-indol
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
EP1065205B1 (en) 1998-03-18 2003-05-28 Taisho Pharmaceutical Co., Ltd Heteroaromatic derivatives
AU747508B2 (en) 1998-03-19 2002-05-16 Nihon Nohyaku Co., Ltd. Arylpiperidine derivatives and use thereof
US6204274B1 (en) 1998-04-29 2001-03-20 American Home Products Corporation Indolyl derivatives as serotonergic agents
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6066637A (en) * 1998-06-19 2000-05-23 American Home Products Corporation Indolyl derivatives as serotonergic agents
ID27976A (id) 1998-06-19 2001-05-03 Lundbeck & Co As H 4,5,6 dan 7-indol dan turunan-turunan indolin, pembuatan dan penggunaannya
CA2335711A1 (en) * 1998-06-19 1999-12-29 Ivan Mikkelsen 4,5,6 and 7-indole and indoline derivatives, their preparation and use
AR020773A1 (es) 1998-10-16 2002-05-29 Duphar Int Res Compuesto derivados de 3-(tetrahidropiridin-4-il)indol, metodo para prepararlo, una composicion farmaceutica que los contiene, metodo para preparar dicha composicion y uso del compuesto
WO2000069424A2 (en) * 1999-05-12 2000-11-23 Solvay Pharmaceuticals B.V. Method of treating psychotic disorders
PL201178B1 (pl) 1999-08-23 2009-03-31 Solvay Pharm Bv Nowe pochodne fenylopiperazyny, sposób ich wytwarzania, kompozycja farmaceutyczna oraz zastosowanie
US6806275B2 (en) 2000-09-13 2004-10-19 Nihon Nohyaku Co., Ltd. Arylpiperidine derivatives and use thereof
AR032712A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
US6903110B2 (en) 2001-07-25 2005-06-07 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
US7235569B2 (en) * 2003-05-02 2007-06-26 Wyeth Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use
CN106243088B (zh) 2015-06-03 2019-01-04 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2675801A (en) * 1954-04-20 Intramedbllary nail
FR2349331A1 (fr) * 1976-04-30 1977-11-25 Roussel Uclaf Nouveaux derives de 2,3 dihydro a/4-(3-indolyl) 1-piperidinyl/methyl 1,4-benzodioxin-2-methanol, un procede pour leur preparation et leur application comme medicaments
GB2044254B (en) 1979-01-26 1983-01-26 Wyeth John & Brother Ltd Piperidine derivatives
US4359468A (en) * 1981-02-25 1982-11-16 Boehringer Ingelheim Ltd. Antiallergic N-[4-(indolyl)-piperidino-alkyl]-benzimidazolones
HU198036B (en) * 1983-08-22 1989-07-28 Hoechst Roussel Pharma Process for production of derivatives of 3-piperidil-/1h/-indasole and medical preparatives containing them
US5256673A (en) * 1983-11-25 1993-10-26 Merck Patent Gesellschaft Mit Beschrankter Haftung Indole-3-yl-A-tetrahydropyridyl or piperidyl compounds
US4548939A (en) * 1984-10-01 1985-10-22 Janssen Pharmaceutica N. V. 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8531665D0 (en) * 1985-12-23 1986-02-05 Wyeth John & Brother Ltd Indole derivatives
JP2860688B2 (ja) * 1990-03-14 1999-02-24 第一製薬株式会社 インドール誘導体
FR2675801A1 (fr) 1991-04-24 1992-10-30 Rhone Poulenc Rorer Sa Piperidines, leur preparation et les medicaments les contenant.
DE4414113A1 (de) * 1994-04-22 1995-10-26 Merck Patent Gmbh 3-Indolylpiperidine
KR102044254B1 (ko) * 2018-01-18 2019-11-13 (주)우신에이펙 배광제어가 가능한 led 탐조등

Also Published As

Publication number Publication date
NO951529L (no) 1995-10-23
DE59504032D1 (de) 1998-12-03
HU9501139D0 (en) 1995-06-28
CN1114651A (zh) 1996-01-10
AU1648895A (en) 1995-11-02
DE4414113A1 (de) 1995-10-26
PL308287A1 (en) 1995-10-30
ATE172730T1 (de) 1998-11-15
DK0683166T3 (da) 1999-07-12
ES2125508T3 (es) 1999-03-01
CA2147451C (en) 2006-03-28
CZ103595A3 (en) 1995-12-13
CZ285369B6 (cs) 1999-07-14
EP0683166B1 (de) 1998-10-28
JPH07291969A (ja) 1995-11-07
EP0683166A1 (de) 1995-11-22
CN1047385C (zh) 1999-12-15
NO307831B1 (no) 2000-06-05
HUT74096A (en) 1996-11-28
KR100361950B1 (ko) 2003-02-05
CA2147451A1 (en) 1995-10-23
UA41333C2 (uk) 2001-09-17
SK280881B6 (sk) 2000-08-14
US5693655A (en) 1997-12-02
RU2151148C1 (ru) 2000-06-20
ZA953260B (en) 1996-01-09
TW401416B (en) 2000-08-11
SK50895A3 (en) 1995-11-08
NO951529D0 (no) 1995-04-21
AU697749B2 (en) 1998-10-15
RU95106675A (ru) 1997-03-20
PL180781B1 (pl) 2001-04-30

Similar Documents

Publication Publication Date Title
KR950032176A (ko) 3-인돌릴피페리딘
PT78633B (de) Verfahren zur herstellung von optisch aktiven carbazol derivaten neue r-und s-carbazol-derivate sowie arzneimittel die diese verbindungen enthalten
KR880006193A (ko) 피페리딘 화합물 및 그의 제조 및 용도
KR910011890A (ko) N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
BR0008015A (pt) Uso de um composto, composto, composições farmacêuticas, e, processo para preparar um composto
PE20010740A1 (es) Aminoacidos biciclicos como agentes farmaceuticos
CA2182593A1 (en) Oral liquid compositions containing paroxetine resinate
KR910015562A (ko) 뇌부전 질환치료용 약제, 신규 2-(1-피페라지닐)-4-페닐시클로알카노 피리미딘 유도체, 및 그의 제법
NO20024241L (no) FremgangsmÕte for fremstilling av citalopram
RU2002102551A (ru) Новые производные пиперазинилалкилтиопиримидина, содержащие их фармацевтические композиции и способ получения активного вещества
US3843796A (en) Antihypertensive agents
RU99110941A (ru) Новые производные 1,7,7-триметил-бицикло[2,2,1] гептана
HUP9901260A2 (hu) Optikailag aktív fenil-pirimidin-származék mint fájdalomcsillapító szer, eljárás előállítására, ezt tartalmazó gyógyszerkészítmény és intermedierje
KR940003953A (ko) 1. 4-벤조디옥산 유도체
EP0521393A2 (en) Diclofenac choline salt, a method for the preparation thereof and pharmaceutical compositions containing it
JPS6341474A (ja) 抗炎症剤
JP4467648B2 (ja) 新規インドールカルボキサミド、医薬組成物およびカルパインの阻害方法
KR920002517A (ko) 칼모둘린 억제 특성을 갖는 벤즈히드릴 유도체 및 그의 제조방법
KR970704685A (ko) 신경이완제로서 유용한 N-치환 아자비시클로헵탄 유도체(N-Substituted Azabicycloheptane Derivatives Useful as Neuroleptics)
KR960014100A (ko) 알킬-5-메틸술포닐벤조일구아니딘 유도체
US4933362A (en) Sunburn treatment composition
EP1749817A1 (en) Neurogenic pain control agent composition
KR910000652A (ko) (1,2,3,4-테트라하이드로-9-아크리딘이미노) 사이클로헥산 카복실산 및 관련 화합물, 이들의 제조방법 및 약제로서의 용도
RU2000107822A (ru) Оптически чистые аналоги камптотецина, оптически чистый промежуточный продукт синтеза и способ его получения
GB1174349A (en) Novel 2-Anilinomethylimidazoline Derivatives and process for the preparation thereof

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee